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DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN OBESE 
ADOLESCENTS USING NON-INVASIVE METHODS 
LAURA LARA-CASTOR 
 
ABSTRACT 
Objective. To identify clinical, socio-demographic, dietary and biological markers 
to be used in a non-invasive and cost-effective clinical tool for screening for non-
alcoholic fatty liver disease (NAFLD) in obese adolescents.  
Methods. We conducted a cross-sectional analysis using baseline data from 77 
obese adolescents enrolled in a drug trial for the Glaser Pediatric Research 
Network, between October 2003 and August 2007. NAFLD was defined as the 
presence of fatty liver infiltration assessed by computed tomography. Receiver 
operation characteristic (ROC) analyses were performed to identify variables with 
the highest area under the curve (AUC) for NAFLD. Serum biomarkers were 
dichotomized using sensitivity analyses to identify the best cutoff point for NAFLD. 
Multiple logistic regression models were created to predict prevalent NAFLD.  
Results. Serum triglycerides was identified as the best biomarker for NAFLD (AUC 
0.790; pseudo R2 0.235). Additional adjustment for sex, age and Tanner stage 
improved the AUC to 0.846 and the pseudo R2 to 0.290. We then explored adding 
a simple biochemical marker for predicting NAFLD (HOMA-B, ALT or glutamate) 
and found that HOMA-B led to greater improvement in AUC, ALT to a greater 
improvement in sensitivity and glutamate to a greater improvement in the pseudo 
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R2. Thus, all three factors individually improved overall model performance to 
some degree and inclusion of all three led to an AUC=0.907 and pseudo R2=0.433. 
Our second objective was to develop a more complex exploratory model starting 
with the inclusion of important clinical predictors (triglycerides, sex, age, Tanner 
stage, SBP, BMI, waist circumference); this yielded an AUC of 0.871 and pseudo 
R2 of 0.342. Further adjustment for HOMA-B, ALT and glutamate gave an 
AUC=0.913 and pseudo R2=0.497.  
Conclusion. Simple clinical and biochemical factors may be used to screen for 
prevalent NAFLD. Our simplest clinically relevant model using triglycerides, age, 
sex and Tanner stage provided a reasonable screening tool for NAFLD in obese 
adolescents. A second more complex model that warrants further testing includes 
triglycerides, sex, age, Tanner stage, SPB, BMI, waist circumference, HOMA-B, 
ALT and glutamate. In this study, this model was more accurate for detecting 
undiagnosed cases of NAFLD in this pediatric population.  
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INTRODUCTION 
Public Health Importance 
Obesity is of special concern in pediatrics as it is highly prevalent (17%)1, tends to 
persist into adulthood and the longer the duration, the more severe the 
complications.2–5 Therefore, more efforts need to be directed toward prevention as 
well as screening and treatment of its comorbidities. One of the most serious 
complications of pediatric obesity and its concurrent metabolic changes is non-
alcoholic fatty liver disease (NAFLD), which involves a spectrum of liver diseases, 
from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH).6–9 Simple 
hepatic steatosis consists of fat accumulation in >5% of the hepatocytes, whereas 
NASH goes along with hepatocyte ballooning, fibrosis and polymorphonuclear 
infiltration.10,11 Pediatric NAFLD remains underdiagnosed,12 even though it is the 
most common cause of liver disease in children.10,3 There is a great need to 
develop non-invasive tools to screen and diagnose NAFLD in at-risk populations 
before its progression to more severe stages and the development of cirrhosis, 
which are associated with a decreased quality of life, high medical costs and high 
mortality.7,12 
Prevalence 
NAFLD affects 10-24% of the general population in the world.13–15 The real 
prevalence of pediatric NAFLD is unknown.12 However, some studies suggest that 
NAFLD affects between 0.7 to 17.3% of the general pediatric population, 38% of 
obese children16 and up to 83% of morbidly obese adolescents.17 NAFLD has been 
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found to be more common in children who are older, of Hispanic ethnicity, are male 
and have a family history of diabetes, obesity and hyperlipidemia.8,3,16,18,19  
Pathogenesis 
NAFLD is considered as the liver expression of the metabolic derangement 
observed in obesity.19–22 Insulin resistance is believed the main driving factor and 
NAFLD is thus associated with obesity, hypertension and dyslipidemia.13,21,23 The 
most currently accepted theory for the development of NAFLD is a “multiple hit” 
process, where genetic, epigenetic and environmental factors play an important 
role in the appearance and progression of the disease.6,9,22,24,25 The first hit is 
recognized as the accumulation of triglycerides in the liver.13,26 The secondary hits 
come with the consecutive oxidative stress and inflammatory processes promoting 
the release of cytokines and reactive oxygen species (ROS), which lead to fibrosis, 
cirrhosis and, in some cases, cancer.7,10,21,23,26 
It is not clear whether liver triglyceride accumulation is the cause or the 
consequence of insulin resistance.25 Liver triglyceride accumulation may occur 
because of an insulin resistance state, which may be associated with prolonged 
exposure to high insulin serum levels27  associated with hyper caloric diets, as well 
as genetic susceptibility and sedentary lifestyles.22,25 Insulin resistance causes 
compensatory hyperinsulinemia and a consequent disruption in lipid metabolism. 
28,29 The tissue uptake of fatty acids from the apolipoproteins is decreased23 as the 
insulin sensitive enzyme lipoprotein lipase (LPL) is not being properly activated to 
breakdown the fatty acids embedded in the chylomicrons and VLDL (very low-
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density lipoproteins).30 The release of free fatty acids (FFA) from the adipocytes is 
increased due to the lack of inhibition of the hormone sensitive lipase by insulin 
and to meet the energetic demands of the body.25,28–31 As a result serum FFA 
increase and these is subsequently delivered to the liver.25,28  As opposed to the 
other tissues, the liver shows an increase in the uptake and synthesis of 
triglycerides and a decrease in lipid beta-oxidation and synthesis of 
apolipoproteins for the export of triglycerides to the blood.9,3,23,24,28 These 
molecular mechanisms are regulated by the transcription factors sterol regulatory 
element-binding protein-1c (SREBP-1c), carbohydrate response element-binding 
protein (ChREBP), and peroxisome proliferator-activated receptor-gamma (PPAR-
γ).3,24,28 An imbalance between the synthesis/uptake of triglycerides versus the 
export/ beta oxidation in liver leads to liver steatosis.28  
The secondary hits come as a consequence of a lipotoxic effect of the FFAs and 
lipid intermediates causing oxidative stress, mitochondrial dysfunction and pro-
inflammatory cytokines contributing to the progression to NASH which is 
characterized by increased fibrosis and consequent cirrhosis.7,9,3,24,28 Some of the 
adipocytokines, adipose tissue substances, that has been found to be involved are 
adiponectin, leptin, resistin and tumor necrosis factor-alpha.12,28 This lipotoxic 
effect aggravates the impaired insulin signaling, which further decreases export of 
triglycerides to the blood.24  Finally, imbalances in gut permeability or in gut 
microbiota might also contribute to the liver damage via gut-derived bacterial 
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products, which have been found to result in the activation of the innate immune 
response and increased fibrogenesis and inflammation.32  
Diagnosis  
The diagnosis of pediatric NAFLD in early stages is difficult due to the need for 
invasive33,34 and costly35 diagnostic procedures, lack of consensus in the 
screening methods and absence of symptoms.22,36–39  
Liver biopsy is currently considered as the gold standard to diagnose NAFLD 
because it allows for the identification of the histopathological stage of the 
hepatocyte, which allows to differentiate simple steatosis from NASH.12,40,41 
However, this technique is highly invasive and costly and is associated with risk of 
bleeding and may also miss the diagnosis due to sampling error given the small 
portion of parenchyma liver examined.33,34,41–43 
Imaging techniques such as ultrasonography, computed tomography (CT), 
magnetic resonance imaging (MRI) and magnetic resonance elastography (MRE) 
have also been used for diagnostic purpose.44,45 CT scan is easy, fast and 
available, and one-slice CT scan, which conveys a low radiation exposure, has 
been identified as a good predictor of NAFLD.46–48 CT scan has the disadvantage 
of not being sensitive enough to differentiate early from more advanced stages 
such as NASH or advanced fibrosis, but it has shown to be good at detecting fatty 
infiltration in the liver and has a better sensitivity than ultrasonography.12,45   
Serum biomarkers and equations derived from these biomarkers are also used in 
practice to screen for NAFLD. Potential biomarkers of NAFLD may markers of 
 5 
energy, lipids and protein metabolism such as alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), AST:ALT ratio, fasting glucose, fasting insulin, 
C-peptide (CPE), the quantitative insulin sensitivity check index (QUICKI), 
homeostatic model assessment for insulin resistance (HOMA-IR), low-density 
lipoproteins (LDL), high-density lipoproteins (HDL), triglycerides.8–10,20,23,49–52 
However, these serum biomarkers alone have usually poor sensitivity for detecting 
NAFLD39,42 The serum biomarker most commonly used clinically to screen for 
NAFLD is ALT.20  ALT not only has found to have low accuracy because other 
conditions can be associated with elevation of ALT, but there is also a lack of 
consensus regarding the threshold for defining abnormal serum levels of ALT, 
especially in pediatric populations.53 Using liver biopsy as gold standard, the 
sensitivity of ALT has been shown to be 57%, well below the conventionally 
accepted 80% sensitivity of a biomarker.54 Given ALT’s low sensitivity and lack of 
other clinically practical alternatives to screen for NAFLD, ALT is used as a 
screening tool but definitely not as diagnostic tool of NAFLD.55,56  
Biomarkers such as markers of cellular injury or apoptosis (caspase generated 
cytokeratin 18, Fas ligand and procollagen III), inflammation (adipokines and 
ferritin), oxidative stress (glutathione peroxidase dismutase, superoxide dismutase 
and oxidized low density lipoprotein) and lipotoxicity45,57 are also associated with 
NAFLD. However, these biomarkers are not readily available in clinical practice, 
thus its utility for screening for NAFLD is low. 
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Recently, the serum long chain polyunsaturated fatty acids (LCPUFAs) omega-6 
(n6) and omega-3 (n3) were identified as potential biomarkers for predicting 
NAFLD. 58–60 In fact, NAFLD has been associated with high serum and liver n6:n3 
ratio. 59–61. An increase in the n6:n3 ratio leads to a decrease in fatty acid oxidation, 
which is caused by the down regulation of the transcription factor peroxisome 
proliferator-activated receptor α (PPAR-α), which in turns blunts the transcription 
of fatty acid oxidation genes, thus decreasing the mitochondrial and peroxisomal 
β-oxidation.62,63 The increase in the n6:n3 ratio also decreases the export of 
triglycerides due to the down regulation of PPAR- α also inhibits the transcription 
of the cytosolic protein liver fatty acid binding protein (LFABP) which influences the 
assembly of very low-density lipoproteins (VLDL).62 Finally, the increased n6:n3 
ratio increases fatty acid synthesis  by an increase in the expression and/or 
processing of the transcription factor SREBP-1 61,63–65 All these metabolic changes 
promote the fatty acid deposition in the liver. LCPUFA serum biomarkers are also 
not readily available in clinical practice. Of note, previous studies validated the 
relationship of dietary n3 and n6 with their correspondent serum levels, and 
dietary, not serum, LCPUFA data has been recommended for use as a proxy of 
serum levels in community studies.66,67  
NAFLD has also been associated with other clinical and socio-demographic 
characteristics such as sex, age, Tanner stage, ethnicity, body mass index (BMI), 
systolic blood pressure (SBP), hypertension, Tanner stage and waist 
circumference.10,19,20,39,49,50,68   
 7 
Formerly evaluated, some clinical predictive models for NAFLD have accounted 
for clinical and socio-demographic characteristics as well as serum biomarkers of 
energy metabolism and inflammation. These clinical predictive models are easy, 
affordable, available and accurate45. The most recent models include the D fibrosis 
score, BARD score, fibrosis-4 score (FIB-4), the Fatty Liver Index, the Framingham 
Steatosis Index and the Pediatric NAFLD Fibrosis Index. 69–73 The D fibrosis score 
includes hyperglycemia, albumin, age, BMI, platelet count and AST:ALT ratio. The 
FIB-4 score utilizes AST, ALT, platelets and age. The Fatty Liver Index uses BMI, 
diagnosis of diabetes, age, sex and AST:ALT. The Framingham Steatosis Index 
includes age, sex, BMI, triglycerides, hypertension, diabetes and the ratio 
AST:ALT and finally, the Pediatric NAFLD Fibrosis Index uses age, waist 
circumference and triglycerides. However, these models, are either only been 
validated in adult population or screen for fibrosis and not for NAFLD from the early 
to late stages. 
Given the increasing prevalence of pediatric NAFLD linked to the obesity epidemic, 
there is a need to identify new cost-effective and non-invasive strategies to 
diagnose NAFLD in its earlier stages.12,39 Most studies target adult population, but 
there is a need to focus on the pediatric population as duration of obesity is 
critical.3,35 Although, biomarkers of NAFLD have been evaluated in a few studies 
of pediatric NAFLD, the accuracy of those indicators using receiver operating 
characteristics (ROC) analysis has not been performed.  Therefore, potential 
clinical models for the screening of NAFLD in pediatric populations have not been 
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tested, even though such a method could provide a critically-needed, a cost 
effective and non-invasive method for identifying subjects with NAFLD. 59,60 
Principal Objective 
We used baseline data available from adolescents enrolled in a multicenter study 
of metformin and lifestyle from the Glaser Pediatric Research Network74 to identify 
biological, clinical, dietary and socio-demographic characteristics strongly 
associated with NAFLD to develop a tool for its screening in a pediatric population. 
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METHODS  
 
General Design 
We conducted a cross-sectional analysis using baseline data (from October 2003 
to August 2007) from 77 obese adolescents enrolled in a clinical trial of metformin 
for the Glaser Pediatric Research Network (GPRN) to identify characteristics most 
strongly correlated with NAFLD among obese adolescents. The study is described 
in more details elsewhere and in the Appendix.74,75  
Inclusion and exclusion criteria of the subjects 
The inclusion criteria for the subjects entered in the study of metformin were as 
follows: ages 13.0 – 17.9 years, BMI ≥95th percentile, weight ≤136 kg. Subjects 
were excluded if they had a diagnosis of diabetes (symptoms of diabetes plus 
casual plasma glucose concentration ≥200 mg/dl (11.1 mmol/l); fasting plasma 
glucose ≥126mg/dl (7.0 mmol/l) or 2 hour plasma glucose ≥200 mg/dl (11.1 mmol/l) 
during an oral glucose tolerance test), prior drug therapy to treat diabetes or insulin 
sensitivity (i.e. insulin, insulin analogs, acarbose, acetihexamide, 
chloropropamide, glimepiride, glipizide, glyburide, metformin, pioglitazone, 
repaglinide, rosiglitazone, tolazamide, tolbutamide or troglitazone), previous 
medication to aid in weight loss (i.e. Benzphetamine Hcl, Diethylpropion Hcl, 
Fenfluramine Hcl, Phendimetrazine Tartrate, Phentermine Hcl or Orlistat, 
Sibutramine Hcl Monohydrate), current medication that might increase metformin 
levels (i.e. Cimetidine, amiloride, digoxin, furosemide, morphine, nifedipine, 
procainamide, ranitidine, triamterene, trimethoprim, vancomycin and quinidine), 
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recent glucorticoid therapy, history of any syndrome or medical disorder 
associated with significant obesity (i.e. Prader Willi Syndrome, Bardet-Biedl 
Syndrome, Cohen Syndrome or Cushing syndrome or disease), prior surgical 
therapy for obesity, recent history of involvement in a formal weight loss program, 
alcohol use (if in the past 6 months had more than 3 alcohol containing beverages 
in a 24hr period and/or consumed alcohol more than twice per week), elevated 
creatinine (>1.2 mg/dl), untreated disorders of thyroid function, elevated liver 
enzymes ALT or AST >80 (approximately 2 times upper limit of normal), mobility 
impairment, other serious medical condition that the principal investigator or the 
lead site investigator determined may put the patient at undue risk if enrolled in the 
study, unable to comply with the protocol in opinion of the principal investigator or 
the lead site investigator, subjects with child-bearing potential who were unwilling 
to remain abstinent or use and effective method for birth control (see 
Appendix).74,75  
Primary outcome for the current cross-sectional analysis 
The primary outcome of this cross-sectional study was the absence of NAFLD 
defined by a cutoff point of 5HU (Hounsfield Units) in fatty liver infiltration assessed 
by CT scan. CT uses X-rays that are collimated to provide a fan-shaped beam that 
is passed through the body, to produce a cross-sectional image of the body region 
scanned. One-slice CT scan implies minimal radiation and has proved to provide 
a good estimate of body composition. 46,47,76 Therefore it doesn’t imply major risk 
unless indicated by the principal or lead investigator (See Appendix). 
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For assessment of fatty liver infiltration, the liver and spleen were visualized using 
a single CT slice at the level of T11-T12 disk space.48 A 5-10 -mm slice collimation 
was acquired through the liver and spleen. Attenuation values of the liver and 
spleen were measured on these images using an operator-defined circular or 
elliptical region-of-interest cursor. Lower attenuation means lower density and thus 
higher fat content. Acquisition of a single CT image is recognized as a practical 
and reliable method for routine measurement of liver fat in research and clinical 
settings.46,48 A cut of point of 5 Hounsfield Units (HU) for the difference (L-S) in 
attenuation between liver (L) and spleen (S) was used to define presence vs. 
absence of fat on liver CT-scan as this value has been shown to be highly 
specific.77  
Secondary measures 
Other variables used in this analysis included demographic (sex and race), 
anthropometric (weight, height, waist circumference), clinical (SBP and Tanner 
stage), biochemical (fasting glucose, fasting insulin, glycosylated hemoglobin 
(HbA1C), CPE, glucagon, leptin, ALT, AST, triglycerides, HDL, glutamate, 
glutamine, leucine, branched chained amino acids (BCAA), binding protein- 1 (BP-
1) and insulin-like growth factor-1 (IGF-1)) and dietary variables (kilocalories, 
protein, carbohydrate, fiber, total fat, polyunsaturated fat, n3, n6, eicosapentanoic 
acid (EPA), docosahexaenoic acid (DHA), glycemic index (GI) and glycemic load 
(GL)).. 
Demographics 
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Race was determined by self-identification. Subjects were asked to choose one or 
more of the following categories: American Indian or Alaska Native, Asian, Native 
Hawaiian or other Pacific Islander, black or African American, white or other. 
Ethnicity was also determined by self-identification by asking whether the subjects 
consider themselves to be Hispanic or Latino. Given the small numbers of subjects 
in some of these categories, we reclassified the race/ethnicity as non-Hispanic 
white, non-Hispanic black, Hispanic/Latino and others.  
Height, weight and Body Mass Index (BMI) 
Height and weight were measured twice using a calibrated wall-mounted 
stadiometer to the nearest 0.1 cm for height and an electronic scale to the nearest 
0.1 kg for weight. The patient weight was measured in light clothing and without 
shoes. A third reading was taken if the difference between the first two readings 
was >0.5 cm for height or 0.3 kg for weight.74 The means of these measurements 
were calculated for the statistical analysis.  
Waist circumference  
Waist circumference was measured by the umbilical method and each measure 
was done twice and the mean was used in the analyses. Subjects were measured 
around the smallest area below the rib cage and above the umbilicus.74,78  
Puberty assessment 
The Tanner staging of pubic hair by direct inspection of a trained clinician was used 
to determine the stage of puberty of adolescents from both sexes. Tanner stage 
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was treated as dichotomous joining stages 2 and 3 because it has been shown 
that the greatest hormonal changes occur in these 2 stages. 68,74  
Youth/Adolescent Questionnaire (YAQ) 
Dietary and supplement intake were estimated for the past year by using the 
validated Youth Adolescent food frequency questionnaire. 79 The questionnaires 
were sent and scored at Channing Laboratory in Boston, MA.  
Clinical Laboratory assessments 
Fasting glucose, fasting insulin, HbA1C, CPE, triglycerides, HDL, ALT, AST, 
glucagon, leptin, fasting amino acids, BP-1 and IGF-1 in serum were obtained from 
the subjects after following a 3-day normal carbohydrate diet (at least 150 g/day) 
and a 10 h fast.74,75 Amino acids levels were available in this study but have not 
previously been evaluated in NAFLD and thus are not reimbursed for this condition 
by third party payer. More details on the measurements can be found in the 
Appendix and elsewhere74.  
Calculated variables 
BMI 
BMI was calculated as the mean weight in kilograms divided by the mean height 
in meters squared and converted to sex- and age specific z-score based on data 
from the Centers for Disease Control and Prevention (CDC).74,80  
Characterization of insulin dynamics and insulin sensitivity  
For this study, fasting insulin and glucose measurements were obtained for 
calculation of both the HOMA and QUICKI indices. The homeostasis model 
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assessment-insulin resistance (HOMA-IR) was calculated as [Fasting Glucose 
(mmol/L) X Fasting Insulin (μIU/ml)] / 22.5. The model assessment of beta-cell 
function (HOMA-β) was calculated as [20 × Fasting Insulin (μIU/ml)] / Fasting 
Glucose (mmol/L) − 3.5.74,81–84  
Institutional approval and informed consent 
Institutional Review Board (IRB) approval were obtained from the five GPRN sites 
and from the Boston Medical Center (BMC). Before the study began, signed 
informed consent and age appropriate assent were obtained from a parent or other 
legal guardian of each subject. In addition, an exempt approval was obtained for 
this NAFLD analysis.74,75  
Statistical Analysis 
We conducted a cross-sectional analysis in 77 adolescent obese subjects to 
identify clinical, socio-demographic, dietary and biological characteristics to 
develop a non-invasive and cost-effective screening tool.  
Exploratory analysis 
Exploratory analyses with histograms and boxplots showed that most of the 
characteristics were not normally distributed, which was confirmed with Shapiro-
Wilk tests for normality.  
Hypothesis testing 
Since several of the biomarkers were not normally distributed and the sample size 
was small, we decided to conduct non-parametric analysis. Wilcoxon tests were 
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used for continuous variables and Fisher’s exact tests for categorical variables. 
Statistical significance was determined as p≤0.05.  
Receiver Operation Characteristics (ROC) analyses 
ROC analyses were performed to obtain the C-statistics (area under the curve, 
AUC) of the different variables associated with NAFLD. The best cutoff point of 
continuous variables were  determined using the cutpt command in STATA and to 
generate a binary variable that would allow for the estimation of the variables’ 
sensitivity, specificity, and percent of correctly classified subjects. Dichotomized 
biomarkers at a set cutoff point is an alternative method to treat non-normally 
distributed biomarkers when log transformation is not desired.85 
Correlation analysis 
Given that many of the variables of interest that were compared were continuous 
vs. continuous but also continuous vs. dichotomous, we used Pearson correlation 
and the point biserial correlation coefficients (mathematically equivalent to 
Pearson correlation) to examine the association variables.  Variables with 
correlation coefficient ≥0.7 were not included in the same model to rule out 
interaction effect.  
Logistic regression analyses 
Simple logistic regression analyses were performed to estimate the odds ratio 
(OR) for NAFLD, as well as AUC, pseudo R2, sensitivity, specificity and percent of 
subjects correctly classified for each variable.   
 16 
After identifying the best predictor using ROC and simple logistic regression 
analyses we build potential models for the screening of NAFLD. Our goal was to 
identify the best model as well as a practical, clinically relevant model using the 
best main predictor adjusted for a few variables. In the attempt of avoiding 
adjustment given the small sample size86, we initially adjusted for a few relevant 
variables. We built a core model with the three clinically relevant variables (age, 
sex and Tanner stage (stages 2 and 3). We further adjusted the model for other 
variables wherever possible.   
Reclassification and log transformation of variables  
Given that many biomarkers were not normally distributed and the limited sample 
size, we tested strategies such as reclassification and log transformation. We 
examined continuous variables before and after log-transformation or classification 
in tertiles. We also created three types of dichotomous variables for those 
continuous variables to identifying NAFLD: 1) joining the 2 less extreme tertiles, 2) 
using the median as cutoff point for NAFLD and 3) the best dichotomous cutoff 
point determined by ROC analysis. Given the stronger associations with NAFLD 
and its easier interpretation of the results, we retained the dichotomous variables 
defined as its best cutoff point in the final analyses. 
Handling of missing data 
From the original 77 subjects, two had missing baseline CT scan data for 
assessing liver infiltration. They were included in the study by substituting with 
outcome data from their second CT scan (week 52 of the metformin trial). We 
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tested possible bias from including these subjects by determining to which group 
of the intervention each of these subjects was assigned and by assessing their 
basal HOMA-B, triglycerides and ALT levels. Both subjects were females. One of 
the subjects had positive CT scan for liver infiltration which was consistent with its 
baseline HOMA-B (634 (Uu/mL) / (mmol/L)), triglycerides (152 mg/dl) and ALT (34 
IU/L) serum levels.  This subject was enrolled in the group treated with metformin, 
but still had NAFLD after the 52 weeks. The other subject had negative CT scan 
for liver infiltration, which also was consistent with its baseline HOMA-B (169 
(Uu/mL) / (mmol/L)), triglycerides (66 mg/dl) and ALT (27 IU/L) serum levels. This 
subject was enrolled in the control group of the metformin study.  
For other variables with missing values, the group mean from all non-missing 
values was substituted for the particular variable. Fasting insulin, HOMA-IR, 
HOMA-B, CPE, QUICKI and HbA1c had 2 missing values. SBP, ALT, AST, 
glucagon, glutamate, glutamine, leucine, BCAA, kcal, protein, carbohydrates, fiber, 
total fat, polyunsaturated fat, n6, n3, EPA, DHA, glycemic index and glycemic load 
had 1 missing value for each.  
All the statistical analysis were performed using STATA 13.  
 
RESULTS 
 
 
The participants median (Q1 [25th percentile] - Q3 [75th percentile]) age of the 
study sample (n = 77) was 14.7(13.7 - 16.0) years old, 26(34%) were male and 
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15(20%) had a Tanner stage of 2 or 3 (Table 1). The study participants were 
49(64%) non-Hispanic white, 16(21%) non-Hispanic black, 7(9%) Asian, 3(4%) 
Hispanic/Latino, 1(1%) other (Hawaiian Pacific/white) and 1(1%) was missing 
value (Table 1). The participants median (Q1 – Q3) BMI was 35.3 (32.3 - 39.3), 
they were all obese and 38(49%) had a BMI ≥99th percentile (Table 1). Using 
one slice CT-scan, the prevalence of NAFLD was 20.8%. The subjects with 
NAFLD were more likely to be male, to be at Tanner stage 2 or 3, to have higher 
SBP, higher levels of fasting insulin, HOMA-B, ALT, AST and triglycerides but 
lower levels of HDL and AST:ALT compared to those without NAFLD (Table 1). 
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15(20%) had a Tanner stage of 2 or 3 (Table 1). The study participants were 
49(64%) non-Hispanic white, 16(21%) non-Hispanic black, 7(9%) Asian, 3(4%) 
Hispanic/Latino, 1(1%) other (Hawaiian Pacific/white) and 1(1%) was missing 
value (Table 1). The participants median (Q1 – Q3) BMI was 35.3 (32.3 - 39.3), 
they were all obese and 38(49%) had a BMI ≥99th percentile (Table 1). Using one 
slice CT-scan, the prevalence of NAFLD was 20.8%. The subjects with NAFLD 
were more likely to be male, to be at Tanner stage 2 or 3, to have higher SBP, 
higher levels of fasting insulin, HOMA-B, ALT, AST and triglycerides but lower 
levels of HDL and AST:ALT compared to those without NAFLD (Table 1).  
 
Table 1. General characteristics  of the subjects 
 
 Median (Q1 - Q3) or n(%) 
Characteristic All subjects With NAFLD Without NAFLD 
n=77  n=16 n=61 
    
Demographics    
    
Age (y) 14.7 (13.7 - 16.0) 14.8 (13.8 - 16.6) 14.7 (13.6 - 15.9) 
Sex (male) 26 (34%) 9 (56%)* 17 (28%) 
Tanner stage (2 or 3) 15 (20%) 6 (38%)* 9 (15%) 
Ethnicity    
   Non Hispanic white 49 (64%) 11 (69%) 38 (62%) 
   Non Hispanic black 16 (21%) 1 (6%) 15 (24%) 
   Asian 7 (9%) 2 (13%) 5 (8%) 
  Hispanic/Latino 3 (4%) 2 (13%) 1 (2%) 
 Other 1 (1%) 0 (0) 1 (2%) 
 Missings 1 (1%) 0 (0) 1 (2%) 
    
Antropomety and clinic    
    
Weight (kg) 98.6 (88.4 - 113.1) 103.1 (93.9 - 113.5) 95.8 (87.9 - 112.2) 
Height (cm) 165.0 (160.0 - 172.2) 167.4 (162.9 - 175.5) 164.1 (159.0 - 170.5) 
	 19 
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BMI (kg/m2) 35.3 (32.3 - 39.3) 34.1 (32.1 - 39.4) 35.670 (32.3 - 39.3) 
BMI z score 2.3 (2.1 - 2.5) 2.3 (2.2 - 2.5) 2.3 (2.1 - 2.5) 
Waist circumference (cm) 103.9 (95.8 - 112.4) 104.7 (97.5 - 112.2) 103.8 (95.3 - 112.6) 
SBP (mmHg) 122.0 (113.5 - 131.5) 126.0 (116.3 - 146.3)* 120.0 (111.6 - 130.0) 
    
Serum biomarkers    
    
Fasting glucose (mg/dL) 92 (85.5 - 97.0) 89.0 (83.3 - 94.8) 93.0 (86.0 - 98.0) 
Fasting insulin (μU/mL) 15.0 (10.0 - 24.0) 20.1 (13.8 - 26.8)* 14.0 (9.5 - 23.5) 
HbA1c (%) 5.4 (5.2 - 5.6) 5.4 (5.1 - 5.6) 5.4 (5.2 - 5.6) 
HOMA-IR (mmol/L * uU/mL) 3.5 (2.2 - 5.7) 4.2 (2.9 - 5.6) 3.1 (2.0 - 5.7) 
HOMA-B ((Uu/mL) / 
(mmol/L)) 206.3 (154.0 - 337.3) 293.1 (205.3 - 612.2)* 188.5 (122.7 - 268.0) 
Quicki 0.14 (0.13 - 0.15) 0.14 (0.13 - 0.14) 0.14 (0.13 - 0.15) 
CPE 3.4 (2.6 - 4.4) 3.6 (2.7 - 4.4) 3.3 (2.6 - 4.3) 
Glucagon 100.0 (87.0 - 116.0) 107.0 (87.3 - 124.8) 98.0 (86.5 - 114.5) 
Leptin 33.0 (23.0 - 47.5) 24.0 (15.3 - 43.3) 37.0 (24.5 - 47.5) 
ALT (IU/L) 19.0 (15.0 - 27.0) 27.5 (19.3 - 43.3)* 17.0 (14.0 - 22.0) 
AST (IU/L) 23.0 (19.0 - 27.5) 28.0 (22.3 - 31.5)* 22.0 (19.0 - 25.0) 
AST/ ALT 1.1 (1.0 - 1.4) 1.0 (0.7 - 1.1)* 1.2 (1.0 - 1.5) 
HDL (mg/dL) 40.0 (32.5 - 44.5) 34.0 (31.0 - 40.0)* 40.0 (34.0 - 45.0) 
Triglyceride (mg/dL) 105.0 (65.0 - 136.5) 148.5 (115.3 - 289.3)* 88.0 (59.5 - 120.5) 
Glutamate  (μmol/L) 61.0 (40.5- 82.0) 72.5 (61.0 - 84.3) 58.0 (38.5 - 81.0) 
Glutamine (μmol/L) 511.0 (463.5 - 550.0) 516.5 (455.8 - 542.0) 508.0 (467.0 - 566.5) 
Glutamine: Glutamate   8.2 (5.7 - 13.3) 7.2 (5.7 - 9.2) 9.3 (5.7 - 14.6) 
Leucine (μmol/L) 118.0 (109.5 - 135.0) 125.0 (114.5 - 145.5) 117.0 (108.5 - 131.5) 
BCAA (μmol/L) 413.0 (368.5 - 458.5) 433.5 (374.3 - 484.5) 413.0 (367.0 - 450.5) 
Bp1 2.0 (0.5 - 3.0) 0.5 (0.5 - 2.0) 2.0 (0.5 - 3.0) 
IGF1 (ng/ml) 302.0 (229.0 - 386.0) 286.0 (201.3 - 451.0) 312.0 (229.0 - 379.5) 
    
Diet    
    
Kcal  1772 (1211 - 2197) 1806 (1195 - 2204) 1671 (1191 - 2197) 
Protein (g) 75.3 (50.6 - 94.8) 69.8 (46.5 - 97.7) 76.8 (50.6 - 93.5) 
Carbohydrates (g) 223.3 (150.0 - 278.2) 227.9 (124.4 - 301.6) 223.3 (153.1 - 227.2) 
Fiber (g) 14.1 (9.7 - 17.7) 13.6 (10.0 -19.0) 14.1 (9.6 - 17.5) 
Total fat (g) 61.8 (45.3 - 81.7) 66.1 (47.2 - 80.4) 59.7 (44.6 - 82.7) 
Polyunsaturated fat (g) 12.0 (9.1 - 15.5) 13.0 (10.0 - 15.2) 12.0 (8.9 - 16.1) 
Omega 6, n6 (g) 11.8 (8.7 – 15.4) 12.9 (9.5 – 15.3) 11.2 (8.6 – 15.5) 
Omega 3, n3 (mg) 60.0 (20.0 - 120.0) 60.0 (20.0 -120.0) 20.0 (17.5 - 60.0) 
n6/n3 243.2 (98.4 – 497.4) 292.5 (98.3 – 436.4) 238.0 (93.9 – 521.8) 
EPA (mg) 10.0 (0.0 - 35.0) 15.0 (0.0 - 40.0) 10.0 (0.0 - 30.0) 
DHA (mg) 40.0 (20.0 - 85.0) 45.0 (20.0 - 87.5) 40.0 (20.0 - 85.0) 
Glycemic index 52.4 (50.3 - 55.1) 51.4 (49.7 - 53.1) 53.1 (50.7 - 55.5) 
	 20 
Glycemic load  116.7 (77.6 – 149.7)  109.5 (64.2 – 158.1)  116.7 (79.3 – 148.4)  
Data are median (Q1 [25th percentile] – Q3 [75th percentile]) or counts and percent (n(%)), as 
appropriate. 
*p≤0.05 from Fisher and Wilcoxon test for binary test and continuous variables respectively. 
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Glycemic load 116.7 (77.6 - 149.7) 109.5 (64.2 - 158.1) 116.7 (79.3 - 148.4) 
Data are median (Q1 [25th percentile] - Q3 [75th percentile]) or counts and percent (n(%)), as 
appropriate 
*p≤0.05 from Fisher and Wilcoxon test for binary test and continuous variables respectively 
 
Table 2 provides data on the performance of a number of biomarkers and other 
subject characteristics for diagnosing NAFLD. The biomarkers with the best 
sensitivity (88%) of NAFLD included triglycerides, while those with the highest 
specificity estimate (≥80%) included Tanner stage, ALT and AST (Table 2). None 
of the biomarkers had both a sensitivity and specificity greater than 80% and none 
had an AUC above 80%. The biomarkers with the best AUC were triglycerides 
(0.79), HOMA-B (0.74) and ALT (0.76) (Table 2). Simple logistic regression 
analyses were done to estimate the relative odds of having NAFLD associated with 
individual characteristics or biomarkers and to help to identify important factors for 
inclusion in subsequent models. (Table 2).  
Since ALT is the most commonly biomarker used in practice for detecting NAFLD, 
we tested the C-statistics for cutoff points conventionally utilized in hospitals53. A 
cutoff point of 40 UI/L decreased the sensitivity to 31.3% (95% CI, 11.0 to 58.7) 
and the AUC to 0.62 (0.50 - 0.74). A cutoff point of 50 UI/L decreased the sensitivity 
to 12.5% (95% CI, 1.6 – 38.3) and the AUC to 0.54 (95% CI, 0.45 – 0.63). 
Using unadjusted predictors of NAFLD and ROC analysis, triglycerides, HOMA-B, 
ALT and glutamate had the odds ratio and best AUC (Table 3) (Figure 1). Since  
ALT is known to be a better marker of NAFLD while AST is a better marker of 
hepatitis from other conditions and alterations in other organs (i.e. heart, muscle 
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and kidney)87, we used ALT rather than AST in the models. We selected 
triglycerides as the main predictor of NAFLD because of the magnitude of its 
association in the logistic regression analysis (OR: 16.7, 95% CI, [3.4 to 81.2]) and 
higher ROC analysis (AUC 0.79, 95% CI, [0.69 to 0.89]).  
A clinically practical model (Core A) was first constructed; triglycerides, age, sex 
and Tanner stage were retained in this model. Next, we explored the addition of 
several other important clinical variables to the Core A model, including BMI, waist 
circumference, SBP, HOMA-B, ALT and glutamate.  
After adjusting for sex, age and Tanner stage (Core A model), improved the AUC 
from 0.79 to 0.85, above the cutoff (>0.80) for identifying a good diagnostic tool 
(Table 3)(Figure 2, graph A).88 Further adjustment for one biochemical variable at 
a time showed improvement in the AUC estimates (Table 3). The best simple 
models were those models that included Core A variables of triglycerides, age, sex 
and Tanner stage plus a single additional biomarker for NAFLD (Core A + 1 in 
Table 3). We selected the best clinically relevant model as the one with Core A + 
BMI (AUC 0.85) given that BMI is a more readily available measurement than waist 
circumference, SBP, HOMA-B, ALT and glutamate (Table 3) (Figure 2, graph C). 
In these analyses we found that HOMA-B led to greater improvement in AUC, ALT 
to a greater improvement in sensitivity and glutamate to a greater improvement in 
the pseudo R2. Thus, all three factors individually improved overall model 
performance to some degree and inclusion of all three led to an AUC=0.91 and 
pseudo R2=0.43.  
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We later generated a second core model (Core B) to adjust for more clinical 
relevant variables including not only sex, age and Tanner stage, but also SBP, BMI 
and waist circumference. This model had a higher AUC and pseudo R2 than Core 
A (Table 3) (Figure 2, graph B). Adjustment for additional variable using the Core 
B compared to Core A, showed improvement in the AUC and the pseudo R2. The 
best of these models was Core B adjusted for HOMA-B, ALT and glutamate with 
AUC of 0.91 and pseudo R2 of 0.50 (Table 3) (Figure 2, graph D).  However, the 
adjusted odds ratio estimates for triglycerides in this final model was less precise. 
The sensitivity, specificity and percent of correctly classified subjects varied based 
on the co-variates added to models (Table 3).  
The sample size in this study was small and therefore we were aware that we 
risked over-specifying the predictive model when too many variables were added. 
We tested the impact of adding other explanatory variables to the model in terms 
of the model’s overall performance and the precision of the triglyceride estimate. 
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Table 2. ROC and simple logistic regression analyses  
 
Cutoff 
point 
Below 
cutoff 
point, 
n(%) 
Correctly 
classified, 
n(%) 
Sensitivity, 
Estimate 
(95% CI), % 
Specificity, 
Estimate 
(95% CI), % 
Area Under the 
Curve, Estimate 
(95% CI) 
Odds Ratio for 
triglycerides, 
Estimate (95% 
CI) 
        
Continous predictors        
        
Age (y) -- -- -- -- -- 0.53 (0.37 - 0.69) 1.1 (0.7 - 1.6) 
Systolic Blood Pressure 
(mmHg) 
-- -- -- -- -- 0.64 (0.48 - 0.81) 1.0 (1.0 - 1.1) 
BMI (kg/m2) -- -- -- -- -- 0.49 (0.33 - 0.65) 1.0 (0.9 - 1.1) 
Waist circumference (cm) -- -- -- -- -- 0.54 (0.39 - 0.70) 1.0 (1.0 - 1.1) 
        
Binary variables        
        
Sex (male) -- 26 (34%) 53 (69%) 56%(30 - 80) 72% (59 - 83) 0.64 (0.50 - 0.78) 3.3 (1.1 - 10.4) 
Tanner stage (2 and 3) -- 15 (19%) 58 (73%) 38% (15 - 65) 85% (74 - 93) 0.61 (0.48 - 0.74) 3.5 (1.1 - 11.6) 
Fasting insulin (μU/mL) 15.5 34 (56%) 45 (58%) 69% (41 - 89) 56% (42 - 69) 0.62 (0.49 - 0.76) 2.8 (0.9 - 8.6) 
HOMA-B ((Uu/mL) / (mmol/L)) 247.9 49 (64%) 57 (74%) 75% (48 - 93) 74% (61 - 84) 0.74 (0.62 - 0.87) 8.4 (2.5 - 28.5) 
HOMA-IR ((Uu/mL) / 
(mmol/L)) 
3.7 39 (51%) 45 (58%) 69% (41 - 89) 56% (42 - 69) 0.62 (0.49 - 0.76) 2.8 (0.9 - 8.6) 
Triglyceride (mg/dL) 109.5 45 (58%) 57 (74%) 88% (62 - 98) 71% (57 - 82) 0.79 (0.69 - 0.89) 16.7 (3.4 - 81.2) 
HDL  (mg/dL) 37.5 30 (39%) 28 (36%) 44% (20 - 70) 34% (23 - 48) 0.39 (0.25 - 0.53) 0.4 (0.1 - 1.2) 
ALT (IU/L) 25 56 (73%) 62 (81%) 69% (41 - 89) 84% (72 - 92) 0.76 (0.64 - 0.89) 11.2 (3.3 - 38.1) 
AST (IU/L) 26.5 55 (71%) 59 (77%) 63%(35 – 85) 80% (68 – 89) 0.71 (0.58 – 0.85) 6.8 (2.1 – 21.8) 
AST:ALT 1.1 31 (40%) 31 (40%) 50% (25 - 75) 38% (26 - 51) 0.44 (0.30 - 0.58) 0.61 (0.21 -1.78) 
Glutamate (μmol/L) 63.5 42 (55%) 50 (65%) 75% (48 - 93) 62% (49 - 74) 0.69 (0.56 - 0.81) 5.0 (1.5 - 16.3) 
        
Data is presented as counts and percentage (n(%)) or estimate and 95% confidence interval (95%, CI) as appropriate.  
Below cutoff point applies only for the dichotomous biomarker variables fasting insulin, HOMA-B, HOMA-IR, triglycerides, HDL, ALT, 
AST, AST:ALT and glutamate. For sex it indicates the n(%) of males and for Tanner stage the n(%) of the combined stages 2 and 3.   
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Table 3. Multiple logistic regression models for NAFLD 
 
Sensitivity, 
Estimate 
% 
Specificity, 
Estimate 
% 
Correctly 
classified, 
% 
AUC, 
Estimate 
Pseudo 
R2 
Adjusted 
Pseudo R2 
Odds Ratio for 
triglycerides, 
Estimate (95% CI) 
         
Unadjusted triglycerides 88.0 70.1 79.2 0.790 0.235 0.184 16.7 (3.4 - 81.2) 
        
CORE A (triglycerides*, age, sex, 
Tanner stage) 
62.5 91.8 85.7 0.846 0.290 0.163 18.6 (3.3 - 103.9) 
        
CORE A + 1        
Core A+ BMI 56.3 91.8 84.4 0.853 0.295 0.142 17.4 (3.2 - 96.0) 
Core A + WC 62.5 91.8 85.7 0.848 0.291 0.138 18.2(3.2 - 102.7) 
Core A + SPB 56.3 93.4 85.7 0.870 0.340 0.187 17.2 (3.1 - 95.8) 
Core A  + HOMA-B* 56.3 95.1 87.0 0.887 0.353 0.201 9.2 (1.5 - 55.7) 
Core A + ALT* 68.8 93.4 88.3 0.867 0.357 0.205 11.3 (2.0 - 65.6) 
Core A + glutamate* 50 95.1 85.7 0.882 0.360 0.207 15.0 (2.7 - 85.6) 
        
CORE A + 2        
Core A + HOMA-B* + ALT* 68.8 95.1 89.6 0.893 0.396 0.218 7.0 (1.1 - 44.3) 
Core A + HOMA-B* +  glutamate* 56.3 96.7 88.3 0.893 0.406 0.228 9.6 (1.6 - 57.5) 
Core A +  ALT* + glutamate* 62.5 95.1 88.3 0.900 0.400 0.223 11.3 (1.9 - 65.9) 
        
CORE A + 3        
Core A + HOMA-B* + ALT* + 
glutamate* 
62.5 96.7 89.6 0.907 0.433 0.229 7.8 (1.2 - 49.6) 
        
CORE A + 4        
Core A + HOMA-B* + ALT* + 
glutamate*+ SBP 
68.8 95.1 89.6 0.911 0.468 0.239 7.8 (1.3 - 48.2) 
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CORE B (CORE A + BMI + WC + SBP) 56.3 93.4 85.7 0.871 0.342 0.139 17.7 (3.1 - 98.9) 
        
CORE B + 1        
Core B + HOMA-B* 62.5 95.1 88.3 0.893 0.385 0.157 9.7 (1.6 - 60.1) 
Core B + ALT* 68.8 98.4 92.2 0.865 0.391 0.162 11.5 (1.9 - 69.9) 
Core B + glutamate* 75 96.7 92.2 0.904 0.446 0.271 18.3(2.7 - 122.8) 
        
CORE B + 2        
Core B + HOMA-B* + ALT* 62.5 95.1 88.3 0.891 0.423 0.168 7.3 (1.1 - 49.2) 
Core B + HOMA-B* + glutamate* 68.8 96.7 90.9 0.920 0.469 0.215 13.0 (1.8 - 92.2) 
Core B  + ALT* + glutamate* 68.8 95.1 89.6 0.900 0.479 0.225 15.0 (2.1- 108.5) 
        
CORE B + 3        
Core B + HOMA-B* + ALT* + 
glutamate* 
75 98.4 93.5 0.913 0.497 0.218 11.7  (1.5 - 91.3) 
*Biomarker defined by ROC analysis as its best cut off point for NAFLD.  
Pseudo R2 is McFadden's formula 
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Figure 1 shows the ROC curves for the unadjusted biomarkers triglycerides, ALT, 
HOMA-B and glutamate. Figure 2 illustrates the ROC curves for the multiple 
logistic regression models Core A (AUC 0.84), Core B (AUC 0.87), most clinically 
relevant (AUC 0.85) and best overall model (AUC 0.91). 
 
  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. ROC curves for unadjusted markers of NAFLD  
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FIGURE 2. ROC for Core A, Core B, clinically relevant and best overall 
multiple logistic regression models for NAFLD 
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FIGURE 2. ROC for Core A, Core B, clinically relevant and best overall 
multiple logistic regression models for NAFLD  
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DISCUSSION 
 
Blood triglycerides were the best biomarker for the screening of NAFLD in 
this cross-sectional analysis of obese adolescents. The blood biomarkers ALT, 
HOMA-B and glutamate, were also good individual predictors for NAFLD. 
Adjustment for age, sex and Tanner stage improved the AUC of the model. Further 
adjustment for BMI, SBP, waist circumference, HOMA-B, ALT and glutamate, 
provided even better estimates and AUC.  
As shown elsewhere, age, sex, ethnicity, BMI, hypertension, waist circumference, 
fasting glucose, triglycerides, ALT and AST are known characteristics associated 
with NAFLD in adult and pediatric populations.8–10,12,19,20,23,39,45,49,50,52  In addition, 
we have observed that protein metabolism markers such as glutamate are also 
predictors of NAFLD in obese adolescents.  
While ALT is the most commonly used biomarker to screen for NAFLD, the lack of 
consensus the optimal cutoff value for predicting NAFLD in children and 
adolescents53 highlights the importance of finding other predictors to screen for 
this disease. What is more, ALT is frequently found to be at the normal range in 
children with NAFLD.12 Therefore, we aimed to develop a clinical tool that could 
screen for NAFLD that had a better AUC than ALT or another individual marker. 
Even though similar models have been developed for adult populations50,73, 
research in pediatric population is scarce.12 Except for the diagnosis of NASH50, 
we are not aware of the availability of non-invasive comprehensive models of 
NAFLD in clinical practice.  Given the importance of detecting the disease before 
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it advances to more severe stages, the development of such a screening tool is of 
great importance.  
Currently, the most accepted theory for the development of NAFLD is a 
multifactorial process, including insulin resistance, liver triglycerides accumulation, 
high BMI, male gender, Hispanic ethnicity, genetics, low physical activity and a 
poor diet among others.22 Therefore, it is important to develop a predictive model 
that accounts for most of these covariates. 
Confirming findings of Schwimmer et al.53 and Manco et al.89, we found that the 
best cutoff point for ALT for detecting NAFLD in this sample was lower than what 
is commonly used in clinic for screening for NAFLD (50 UI/L [30 to 90] for boys 
and 40 UI/L [29 to 65] for girls. When a cutoff point is set too high, it might lead an 
underdiagnoses of the disease. Therefore, these higher cutoff values for NAFLD 
screening will lead to substantial underdiagnoses of the disease, a finding that has 
critically important implications since the longer the duration of NAFLD, the more 
severe the complications will be prior to diagnosis, which means greater medical 
costs, lower quality of life and possibly premature death.  
The high association of triglycerides with NAFLD in this analysis is consistent with 
other studies.20,23,49,50,90 The multiple logistic regression models had lower 
sensitivity but higher specificity than the unadjusted triglycerides. The models also 
showed higher AUC and they explained more of the variance (greater pseudo R2), 
as well as higher percent of subjects were classified correctly classified compared 
to the simple logistic regression analyses (Table 3). In this analysis we found that 
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the blood biomarkers ALT, HOMA-B and glutamate, could be used as a surrogate 
marker in screening for NAFLD given the small differences in the AUC with 
triglycerides. 
The high accuracy of our multiple logistic regression models labeled as Core A 
and Core B, suggests that they may be good non-invasive and cost effective tools 
to implement in clinical practice for the screening of NAFLD after further validation 
in larger samples. We selected the Core A model adjusted for BMI as the best 
clinically relevant model since BMI is a readily available measurement and it 
showed to improve the C-statistics of the model.  
We also found that further adjustment for an additional biomarker improved the 
AUC and pseudo R2. We selected the Core B model adjusted for HOMA-B, ALT, 
and glutamate as the best overall model given its best combination of sensitivity, 
specificity, AUC, pseudo R2 and percent of correctly classified subjects. Since this 
is a pilot study, we cannot confirm the inclusion of such variables for a screening 
tool, but only recommend to test this models in a larger sample before application 
in clinical practice.  
As opposed to other studies, some biomarkers were not as strongly associated 
with NAFLD (i.e., fasting glucose, fasting insulin, CPE, AST/ALT, HDL and 
leptin).20,49,50,91 Leptin is an adipocytokine that has been found to be protective 
against the development of NAFLD in adolescents given its influence on increasing 
energy expenditure and decreasing food intake.91 However, in our sample the 
difference in leptin levels between groups was not statistically significant, and did 
  31  
 
not have a strong AUC for predicting NAFLD. This lack of association in our sample 
may be the best explained by the exclusion in this sample of patients with weight 
>136 kg. 
As opposed to other adult and pediatric studies59,60,92, none of the dietary variables 
in our study had a strong association with NAFLD. The lack of association between 
dietary variables and NAFLD in our study may be explained by the small sample 
size, high levels of random error form the food frequency methodology and 
potential for bias in the dietary intake estimates.  
The main limitation of this pilot study is its sample size, which limits the creation of 
a definitive tool for the screening of NAFLD. This may explain why the odds ratio 
were large and their confidence intervals spread. The study sample size and 
recruitment procedures may explain the prevalence of NAFLD, which has been 
reported to be between 30% and 83% in other obese and morbidly obese pediatric 
population.16,17 In other studies, Hispanics have been found to be more likely than 
non-Hispanics blacks or whites, and Asians to have NAFLD.16 Given the limited 
sample size, we were not able to examine the relationship of race and ethnicity 
with NAFLD. Finally, age and BMI were identified as confounders of the 
relationship between triglyceride and NAFLD but not as predictors of NAFDL. A 
study with a broader range of age and BMI or with a larger sample size would be 
needed to revise the predictive value of these factors in the screening instrument.  
However, our study has specific strengths. In first place, we did a careful statistical 
analysis, selecting non-parametric over parametric methods given that the 
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distribution of several variables was not normal in our sample. We also 
corroborated that the variables entered in the models were not correlated for more 
than 0.7, to avoid over inflation of the results. We tested the inclusion of study 
variables to eliminate errors derived by the non-normal distribution.  
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CONCLUSION 
We successfully identified substantial biomarkers for the screening of NAFLD that 
could be used in clinical practice. Blood triglycerides were the best marker for the 
screening of NAFLD. A clinically relevant model using triglycerides, age, sex and 
Tanner stage showed to be a good screening tool for NAFLD in obese 
adolescents. We believe that a multivariate screening tool that includes 
triglycerides, sex, age, Tanner stage, SPB, BMI, waist circumference, HOMA-B, 
ALT and glutamate will provide much greater accuracy for detecting undiagnosed 
cases of NAFLD in pediatric populations. This pilot study provided the data to 
define the sample needed to conduct larger validation studies to provide a clinical 
tool to screen for NAFLD and thus help manage NAFLD among obese adolescents 
in earlier stages. 
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APPENDIX 
 
Insights about the clinical trial of metformin and lifestyle 
The metformin study was a multicenter, randomized, placebo controlled, double 
blinded trial, designed to test the hypothesis that 48 weeks of treatment with 
metformin would decrease the BMI of obese adolescents. The study had a duration 
of 124 weeks in total, going from October 2003 to August 2007. There were 2 
Enrollment phases, one anticipated at week 0 and another one at week 24. Each 
Enrollment phase had a length of 24 weeks.74,75 
Study enrollment 
Recruitment  
The hospitals forming part of the GPRN were Packard Children´s Hospital, 
Stanford University School of Medicine; Texas Children´s Hospital, Baylor College 
of Medicine; Children’s Medical Center, University of California San Francisco; 
Mattel Children’s Hospital, University of California, Los Angeles and Children’s 
Hospital Boston and Harvard Medical School.75 Each of the 5 participant sites 
screened approximately 25-30 subjects. Enrollment and screening took 
approximately 24 weeks. 
Recruitment from clinic and hospital databases 
Prospective subjects who met the appropriate age and approximate BMI criteria 
were identified during review of the hospital database or referred by their personal 
physicians in the pediatric clinics at the five participating institutions, as well as 
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from local private and community practices. Methods of recruitment included 
invitations by the patient’s physician during a clinic visit, or a letter of invitation from 
the patient’s physician to the prospective subjects.  
Advertisements 
All advertisements were approved by each institution’s Institutional Review Board. 
Minority recruitment 
One of the goals of the study is to determine the impact race/ethnicity has on the 
outcome measured. Investigators and support staff at all five participating 
institutions were strongly encourage to recruit minority subjects into the study.  
Initial contact and pre-screening encounter 
If a prospective subject expressed interest in the study, the Nurse Coordinator, 
under the direction of the Lead Site Investigator, met the subject and his/her parent 
or legal guardian in clinic, or contacted the subject by phone to review the study 
and complete a pre-screening encounter.  
Pre-screening encounter 
The subject (and parent or legal guardian) was questioned regarding inclusion and 
exclusion criteria. In addition, potential subjects were asked about how they heard 
about the study in order to focus future recruitment efforts. If they were not planning 
to participate in the study, reasons for not doing so were assessed and recorded. 
Subjects who met the non-laboratory eligibility criteria and who were interested in 
participating were consented and schedule for a Screening visit. If the subject was 
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contacted by phone for pre-screening, consent was obtained at the beginning of 
the Screening visit.  
Study registry 
Each of the five participating institutions maintained a cumulative record of all 
potential subjects that were pre-screened at that site. This registry included data 
regarding how the potential subjects were identified, whether they agreed to be 
part of the study, and if not, why not.  By comparing non-enrolled subjects to 
enrolled subjects, recruitment can be optimized over time.   
Informed Consent process 
Informed consent was obtained prior to screening procedures, either during the 
initial pre-screening contact with subjects in clinic, or immediately prior to initiation 
the Screening visit. The subject (and parent or legal guardian) were given the 
consent form (and assent form) to read, and the Lead Site Investigator was 
available to review the study, clarify any areas that were confusing and answer 
any questions. The purpose, study duration, procedures, potential risk and benefits 
and the subject’s rights were explained. The subjects were instructed that 
participation was voluntary and that s/he was free to withdraw at any time. It was 
also noted that the subject may be withdrawn by the Principal or Lead Site 
Investigator at any time.  
By asking the subject to explain the study in his/her own words, it was assessed 
the subject’s understanding and autonomy. Each subject was informed that access 
to his/her medical records and trial related source documents will be granted for 
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research related monitoring, IRB review, and regulatory inspection. Subjects were 
also informed that if abnormal test results that could affect the care they receive 
from their primary care physician were obtained during the screening process, their 
tests results were going to be provided to their physician.  
Overview of visit assessments and procedures of the study of metformin 
Screening visit 
The screening visit consisted in obtaining the following: informed content (if subject 
and parent had not yet completed the consent form), contact information, 
measurement of subject’s height and weight (in order to calculate BMI), a medical 
history and use of concomitant medications.  
Baseline visit 
The baseline visit occurred in the same day as the Screening visit, or as late as 8 
weeks after the screening visit. The baseline visit consisted on the following: 
obtaining subject’s medical history, assessing use of concomitant medications, 
physical exam, a CT scan, a DXA scan, clinical laboratory assessments (blood and 
urine), and the Youth/Adolescent Food Frequency questionnaire. Contact 
information was confirmed.  
History, physical exam and laboratory assessments 
Contact information 
Basic contact information was obtained for each subject, their parent or legal 
guardian, and for additional person (to call in case of emergency). This contact 
information was located in the subject’s study file. 
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Initial medical history 
A complete medical history of the subject was ascertained at the Screening visit. 
This included a chart review and an interview for a comprehensive medical history 
(including menstrual history, review of systems and family health history), as well 
as basic demographic information.  
Initial physical exam  
The initial physical exam took place at the Baseline visit and included height, 
weight and Tanner staging. 
Concomitant medication review 
Concomitant medications are defined as over-the-counter and prescription 
medications, vitamin and mineral supplements, and herbal supplements. 
Assessment for use of concomitant medications took place at screening and 
baseline visits and all medications were recorded.  
Clinical Laboratory assessments 
Blood and/or urine specimens were collected at Baseline visit. 
Fasting insulin concentrations 
These methods include glucose clamps and related procedures that involve the 
infusion of insulin. Because of the risk associated with glucose clamps, this 
procedure was not used in this study. Numerous algorithms utilize insulin and 
glucose data obtained during either oral or intravenous glucose tolerance tests in 
order to calculate surrogate measures of insulin production and insulin sensitivity. 
The ratio of glucose to insulin and data from oral glucose tolerance testing (OGTT) 
  39  
 
have been used as markers of insulin sensitivity, but show limited overall 
correlation with more precise measures as clamp studies. 
Fasting insulin concentrations can be combined with fasting glucose 
concentrations using an algorithm to estimate insulin sensitivity. Of the available 
algorithms, the homeostasis model assessment (HOMA) and the quantitative 
insulin sensitivity check (QUICKI) have the most extensive published validation 
data.74,81–84 
Radiology studies 
Each subject underwent CT and DXA scanning during the study. The CT and DXA 
scans were read centrally and results of these scans were not provided directly to 
subjects.  
Computed Tomography (CT) 
A 2-slice CT scan was obtained to characterize abdominal fat distribution as 
visceral or subcutaneous, and one slice was obtained to assess fatty liver 
infiltration of the liver. Abdominal two-slice CT scan was obtained on each subject 
at baseline visit. The CT scans were GE, Siemens, or Philips equipment, 
depending on the center and they were analyzed at Harvard Medical School with 
a standard software program (Photoshop CS2, Adobe Systems, San Jose).75 
Pregnancy was ruled out by a urine pregnancy test BEFORE the CT scan was 
performed.74 
Clinical Laboratory Assessments 
Safety Labs 
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Urine pregnancy test 
A pregnancy test was obtained at baseline visit. All females that had begun 
menstruating had a urine pregnancy test. Pregnancy tests results must be negative 
prior to performance of the CT and DXA scans.  
Other Labs 
Oral Glucose Tolerance Test 
Subjects were also assessed for 3-hour glucose tolerance test (OGTT; 75g of 
glucose). The OGTT included 7 measurements of glucose and insulin, and 6 
measurements of C-peptide.  
Glucose and insulin were measured as part of an extended OGTT at 0 minutes 
(immediately before), and at 15, 30, 60, 90, 120 and 180 minutes after 
consumption of a standard oral glucose load.  
Insulin and IGFBP-1 were measured by two-site immunochemiluminometric 
assays with sensitivities of 0.6 μU/ml and 1 ng/ml respectively.  The ranges for the 
IGFBP-1 are pre-pubertal (fasting) 30-1000 ng/ml and pubertal (fasting) 20-200 
ng/ml.74  
C-peptide were measured at 0 minutes (immediately before), and at 15, 30, 60, 
120 and 180 minutes after consumption of an oral glucose load. C-peptide was not 
measured at 90 minutes.  
If the OGTT results in either a fasting plasma glucose ≥126 mg/dl or a 2-hour 
plasma glucose ≥200 mg/dl, the subject was instructed to return to the lab for a 
standard 2-hour GTT (with fasting and 2-hour post prandial glucose 
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measurements). If either results of the 2-hour GTT were elevated, a diagnosis of 
diabetes was confirmed. The Principal or Lead Site Investigator was responsible 
for confirming that the subject was referred to diabetes treatment.  
Insulin was measured by two-site immunochemiluminometric assays with 
sensitivities of 0.6 μU/ml.  
● Hemoglobin A1c (Hgb A1c) 
● Lipid Panel (TG) 
Triglycerides, total cholesterol, low-density lipoproteins (LDL) and high-density 
lipoproteins (HDL) were measured.  
Fasting amino acids. Fasting plasma samples for amino acids were stored 
frozen at –70°C until analyzed by using ion-exchange liquid chromatography 
(Amino Analyzer L-8800; Hitachi, Tokyo, Japan) at the Children’s Hospital of 
Boston Chemistry Laboratory, Boston. 
Laboratory Specimen Handling and Analysis 
Most laboratory assays were performed at Esoterix Clinical Trial Services, 
Calabasas Hill, CA. Laboratory assays were performed at Esoterix Clinical Trial 
Services, Calabasas Hill, CA. This laboratory also provided the reference range 
data used for the analyses.74,75   
 
DATA HANDLING AND RECORD KEEPING 
Data collection and Handling 
Source Documents 
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Study data was extracted from source documents. Source documents included 
original documents and data (included but not limited to hospital records [physical 
or electronic], clinical and office charts, worksheets developed for this study, 
laboratory notes, memoranda, subjects’ calendars or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copies 
or transcriptions, microfiches, photographic negatives, microfilm or magnetic 
media and x-rays, wherever the foregoing bay be kept). Source documents were 
provided to a sponsor audit committee or monitor (to ensure compliance to the 
protocol), for IRB review, or to regulatory inspectors if requested.  
Study Data 
Study data, extracted from source documents, includes all information developed 
in the performance of this study as compiled and delivered to the sponsor in 
accordance with the study protocol, including, but not limited to, the case report 
forms generated by each participating member institution.  
Confidentiality of Source Documents and Study Data 
An unambiguous subject identification code was used in lieu of the subjects’ name 
on all study data compiled and delivered by the participating institution to the 
sponsor (or other party contracted by the sponsor). This subject identification code 
included the subjects’ initials, the site number and subject number. A key for this 
code was maintained at the site and kept separate from study files. All source 
documents and study data were kept confidential.  
Study Data Maintenance, Management and Ownership 
  43  
 
All the study data is owned by the sponsor (the Elizabeth Glaser Pediatric 
Research Foundation). All study data was maintained and managed in compliance 
with FDA and ICH/GCP standards and as agreed upon by the Network and 
participating institutions. Also, in accordance with the Network Agreement, 
participating institutions will have access to all study data collected at every 
participating institution, to be utilized for research and educational purposes, but 
each participating institution may only publish and present any data collected by 
that institution as described in the publication policy below.  
Gender and Ethic Diversity 
The female to male ratio was 1:1. The ethnic distribution was expected to reflect 
the distribution at each site. Each institution recruited according to the populations 
served. The estimated distribution for each institution is described in the individual 
IRB applications.  
Risk and Benefits 
Risks 
Risks to subjects included the following: 
1) Radiation   exposure: ***The risk refers to the complete study, which 
includes 3 CT scans and 3 DXAs. 
2) Phlebotomy: Blood draw amounts will fall below the acceptable range 
designated by site IRB’s. Risk include minimal temporary discomfort, 
possibly a small amount of bruising, and rarely infection. Phlebotomy was 
performed by pediatric-trained personnel with proper technique for 
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minimizing risks of hematoma and infection. EMLA® or ElaMax® cream 
was offered to all subjects to minimize discomfort. There is a slight risk of 
an allergic reaction to the EMLA® or ElaMax® cream.  
3) Questionnaires: Information is straightforward and non-threatening. 
4) Confidentiality: Was strictly maintained.  
Benefits 
The main benefit was a close evaluation of health status. 
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